In recent years the use of non-invasive biomarkers to assess liver fibrosis has become widely accepted. Although the combination of surrogate markers, such as those employed by the FibroTest, have a high predictive value for the assessment of significant fibrosis, it is important to find tools that can improve its accuracy, particularly in intermediate stages and to reinforce its reliability by ensuring that the classification results are independent of contingent features of the classification technique.